The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Domestic Drug Makers’ Major Products See Sharp Declines in 1st Half; Sales of Aricept, Lipitor Down 30%
November 5, 2012
-
BUSINESS “Lecture Meeting Fever” as Companies Seek New Ways to Interact with Doctors Under Tougher Restrictions on Settai
November 5, 2012
-
BUSINESS Sales Target for Prasugrel Achievable Despite Add’l Indication Dropped: Daiichi Sankyo Pres. Nakayama
November 2, 2012
-
BUSINESS Takeda’s Japan Sales Ratio Likely to Fall to Mid-30% Range: President Hasegawa
November 1, 2012
-
BUSINESS Mochida, MTPC See Signs of Sales Growth for Lexapro after Lifting of Long-Term Prescription Ban
October 31, 2012
-
BUSINESS Shionogi to Take Part in GSK-Pfizer JV, Realigns Strategy in HIV Field
October 30, 2012
-
BUSINESS Chugai to License SGLT-2 Inhibitor to Kowa, Sanofi
October 29, 2012
-
BUSINESS Janssen’s New MR Training System Aims to Produce “Consulting MRs”
October 29, 2012
-
REGULATORY MHLW to Initially Limit Number of Stores to Offer Epadel OTC
October 26, 2012
-
BUSINESS “Changing Way of Thinking Necessary among Industry, Government, Academia for Promotion of Drug Discovery”: AZ Chairman Kato
October 25, 2012
-
BUSINESS Santen Going on Offensive in Growth Fields in Ophthalmology
October 24, 2012
-
BUSINESS Astellas Poised for Domestic PIIb Trial of Novel IBS Treatment
October 23, 2012
-
BUSINESS MTPC to Dissolve Capital Alliance with Choseido
October 22, 2012
-
REGULATORY Sales Tax Hike Expected to Hasten Separation of Dispensing from Medical Practice by Sapping Yakka-Saeki
October 19, 2012
-
REGULATORY PAFSC Committee Recommends Approval for Switch OTC Version of Epadel 2 Years after Frist Review
October 18, 2012
-
BUSINESS Qol’s Mr Takada Hints at Continued Use of Long-Listed Drugs from Makers Hiring Apo Plus MRs
October 17, 2012
-
BUSINESS MTPC’s Oral MS Treatment Charging towards Blockbuster Territory
October 16, 2012
-
BUSINESS Towa Pharmaceutical Expanding Direct-Sales Network as Its Distributors Face Lack of Successors
October 15, 2012
-
ACADEMIA We Would Like to Provide iPS Cells with Medical History Identification: Prof. Yamanaka of Kyoto University
October 15, 2012
-
BUSINESS Radical AD Treatments Hit “PIII Wall” Again, but Amyloid β Hypothesis Remains Unshaken
October 15, 2012
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…